Heidelberg Pharma Reports on First Nine Months of 2026

Heidelberg Pharma AG has highlighted its operational and financial progress for the first nine months of 2026. Significant developments include the Phase IIa trial of HDP-101 in multiple myeloma and new collaboration agreements. The company received approval for clinical trials in China and reported a 79% increase in sales and income compared to the previous year. Cost reduction initiatives decreased expenses by roughly 30%, contributing to a stable financial position.

Pamlectabart tismanitin's Phase IIa study is advancing, and partnerships with companies like Huadong Medicine are expected to drive growth. Financial results show a net loss reduction to EUR 8.7 million from EUR 21.1 million last year, driven by increased revenue and controlled expenses. Cash reserves stood at EUR 19.8 million by the end of the reporting period.